Table 1 Performance of HPV testing methods relative to PCR in head and neck squamous cell carcinoma
From: A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer
No. of HPV+ by test (%) | No. tested | Gold standard: high-risk HPV DNA by MY-PCR | ||||
|---|---|---|---|---|---|---|
Sensitivity (95% CI) | Specificity (95% CI) | Area under the curve (95% CI) a | P-valueb | |||
All sites combined | ||||||
p16 Immunohistochemistry | 19 (20%) | 97 | 52% (32–71) | 93% (84–98) | 0.72 (0.62–0.82) | (Reference) |
In situ hybridization (Ventana) | 41 (47%) | 87 | 59% (39–78) | 58% (45–71) | 0.59 (0.47–0.70) | 0.055 |
In situ hybridization (Dako) | 5 (6.6%) | 76 | 21% (7–42) | 100% (93–100) | 0.60 (0.52–0.69) | 0.042 |
Oropharynx only | ||||||
p16 Immunohistochemistry | 10 (37%) | 27 | 69% (39–91) | 93% (66–100) | 0.81 (0.66–0.96) | (Reference) |
In situ hybridization (Ventana) | 16 (70%) | 23 | 67% (35–90) | 27% (6–61) | 0.47 (0.27–0.67) | 0.000 |
In situ hybridization (Dako) | 4 (21%) | 19 | 40% (12–74) | 100% (66–100) | 0.70 (0.54–0.86) | 0.046 |
Gold standard: HPV16 RNA by RT-PCR | ||||||
No. of HPV+ by test (%) | No. tested | Sensitivity (95% CI) | Specificity (95% CI) | Area under the curve (95% CI) a | P-valueb | |
All sites combined | ||||||
p16 Immunohistochemistry | 18 (23%) | 80 | 56% (35–76) | 93% (82–98) | 0.74 (0.64–0.85) | (Reference) |
In situ hybridization (Ventana) | 35 (48%) | 73 | 67% (45–84) | 61% (46–75) | 0.64 (0.52–0.76) | 0.600 |
In situ hybridization (Dako) | 4 (6%) | 67 | 18% (5–40) | 100% (92–100) | 0.59 (0.51–0.67) | 0.045 |
Oropharynx only | ||||||
p16 Immunohistochemistry | 9 (43%) | 21 | 90 (56–100) | 100% (72–100) | 0.95 (0.85–1.00) | (Reference) |
In situ hybridization (Ventana) | 13 (68%) | 19 | 67% (30–93) | 30% (7–65) | 0.48 (0.26–0.71) | 0.007 |
In situ hybridization (Dako) | 3 (19%) | 16 | 38% (9–76) | 100% (63–100) | 0.69 (0.51–0.87) | 0.034 |
